Pharmacogenomics Analysis
How Sample Subject's genotype is predicted to influence response to common medications, with provider-ready, evidence-graded recommendations. All values below are synthetic and for demonstration only.
Provenance
Provider Alert
| Drug | Gene / Genotype | Evidence | Recommendation | Source |
|---|---|---|---|---|
| ExampleDrug A | GENE1 *2/*2 (rs0000001 AG) |
CPIC Level A | Reduced-function — consider alternative agent; consult your prescribing clinician. | CPIC ↗ |
| ExampleDrug B | GENE2 *1/*17 (rs0000002 CC) |
CPIC Level A | Ultra-rapid metabolizer — standard dose may be sub-therapeutic; monitor response. | CPIC ↗ |
| ExampleDrug C | GENE3 *1/*3 (rs0000003 GT) |
CPIC Level B | Intermediate activity — initiate at standard dose with clinical monitoring. | PubMed ↗ |
| ExampleDrug D | GENE4 *1/*1 (rs0000004 AA) |
CPIC Level C | Normal metabolizer — no genotype-guided change indicated at this time. | PubMed ↗ |
Per-Gene Findings
GENE1 — Reduced Metabolizer
rs0000001
7:1,000,000
AG
Sample Subject carries one reduced-function allele, predicting intermediate enzyme activity, per the CPIC GENE1 guideline. For substrates of this enzyme, exposure may be elevated relative to normal metabolizers.
Historical contextPrior analysis (v1) flagged this region with a provisional call; superseded by the current GRCh37-aligned result.
GENE2 — Ultra-rapid Metabolizer
rs0000002
10:2,000,000
CC
A duplicated active allele predicts ultra-rapid metabolism. Standard doses of affected substrates may yield sub-therapeutic plasma concentrations; therapeutic response should be monitored.
GENE3 — Intermediate Activity
rs0000003
12:3,000,000
GT
Heterozygous genotype associated with modestly reduced transporter activity. Clinical impact is drug-dependent; initiate at standard dose with monitoring.
Historical contextEarlier panel reported this variant under a legacy rsID merge; current annotation reflects the dbSNP build at access date.
GENE4 — Normal Function
rs0000004
4:4,000,000
AA
Reference genotype predicting normal enzyme function. No genotype-guided dosing change is indicated; included for completeness of the panel.
GENE5 — Uncertain Significance
rs0000005
2:5,000,000
CT
Variant of uncertain significance. Reported for transparency; current evidence is insufficient to support a clinical recommendation.
Genotype Table
| rsID | chr:pos | Genotype | Gene | Significance |
|---|---|---|---|---|
rs0000001 | 7:1,000,000 | AG | GENE1 | Tier 1 |
rs0000002 | 10:2,000,000 | CC | GENE2 | Tier 1 |
rs0000003 | 12:3,000,000 | GT | GENE3 | Tier 2 |
rs0000004 | 4:4,000,000 | AA | GENE4 | Tier 2 |
rs0000005 | 2:5,000,000 | CT | GENE5 | Tier 3 |